With AbbVie’s Humira (adalimumab) having now faced biosimilar competition in the US for just over a year – as well as more than five years of erosion in Europe, where biosimilars launched in October 2018 – the originator was always expected to report a significant dent in sales of the once top-selling brand in 2023.
AbbVie Sets Out Expectations For 2024 Humira Competition
Offers Overview Of Anticipated Impact From Adalimumab Biosimilars In The Year Ahead
As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.
